Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

$44.22 +0.75 (+1.73%)

(As of 12/20/2024 05:16 PM ET)

Ultragenyx Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
1

Buy
12

Based on 13 Wall Street analysts who have issued ratings for Ultragenyx Pharmaceutical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for RARE.

Consensus Price Target

$88.46
100.05% Upside

According to the 13 analysts' twelve-month price targets for Ultragenyx Pharmaceutical, the average price target is $88.46. The highest price target for RARE is $127.00, while the lowest price target for RARE is $46.00. The average price target represents a forecasted upside of 100.05% from the current price of $44.22.

Get the Latest News and Ratings for RARE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ultragenyx Pharmaceutical and its competitors.

RARE Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	9 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$88.46	$87.46	$87.43	$89.55
Forecasted Upside	100.05% Upside	85.14% Upside	51.89% Upside	88.52% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

RARE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RARE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ultragenyx Pharmaceutical Stock vs. The Competition

Type	Ultragenyx Pharmaceutical	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	100.05% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent RARE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
12/20/2024	Wells Fargo & Company 3 of 5 stars	Boost Target	Overweight ➝ Overweight	$75.00 ➝ $88.00	+102.44%
11/21/2024	JPMorgan Chase & Co. 3 of 5 stars	Lower Target	Overweight ➝ Overweight	$105.00 ➝ $102.00	+119.54%
11/12/2024	Canaccord Genuity Group 1 of 5 stars	Reiterated Rating	Buy ➝ Buy	$121.00 ➝ $121.00	+147.80%
11/6/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$77.00 ➝ $77.00	+54.96%
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$116.00 ➝ $116.00	+122.31%
11/6/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$82.00 ➝ $95.00	+82.06%
We recommended Palantir in 2021, now we’re recommending this... (Ad) My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$61.00 ➝ $73.00	+33.60%
8/5/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$83.00 ➝ $81.00	+65.04%
8/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$67.00 ➝ $76.00	+55.20%
8/2/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$43.00 ➝ $46.00	+5.65%
5/31/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$83.00 ➝ $76.00	+88.59%
5/31/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$124.00 ➝ $127.00	+217.66%
5/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$68.00 ➝ $72.00	+86.29%
11/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$90.00 ➝ $84.00	+123.34%
10/25/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$135.00 ➝ $130.00	+298.77%
6/7/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$130.00 ➝ $133.00	+158.35%
6/6/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$60.00 ➝ $80.00	+56.10%
2/17/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$96.00	+97.08%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:06 AM ET.

RARE Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Ultragenyx Pharmaceutical is $88.46, with a high forecast of $127.00 and a low forecast of $46.00.
: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RARE shares.
: According to analysts, Ultragenyx Pharmaceutical's stock has a predicted upside of 100.05% based on their 12-month stock forecasts.
: Ultragenyx Pharmaceutical has been rated by research analysts at Canaccord Genuity Group, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Royal Bank of Canada, TD Cowen, and Wells Fargo & Company in the past 90 days.
: Analysts like Ultragenyx Pharmaceutical more than other "medical" companies. The consensus rating score for Ultragenyx Pharmaceutical is 2.92 while the average consensus rating score for "medical" companies is 2.81. Learn more on how RARE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

This page (NASDAQ:RARE) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target